Renal Cell Carcinoma Clinical Trials in New Haven, Connecticut

4 studies are recruiting for renal cell carcinoma in New Haven, Connecticut right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

   The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monother…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEO-811 Connecticut Site, New Haven, Connecticut

   Locations

   12 in total

   Run by

   Neomorph, Inc

   See if you can join NCT07300241 on ClinicalTrials.gov

2. A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

   This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patie…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale - New Haven Hospital, New Haven, Connecticut

   Locations

   20 in total

   Run by

   HiberCell, Inc.

   See if you can join NCT06234605 on ClinicalTrials.gov

3. Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

   This Phase II trial will evaluate progression-free survival after Stereotactic Body Radiation Therapy to oligoprogressive (1-5) lesions in metastatic renal cell carcinoma patients on any immune checkpoint inhibitor-containing regimen with last dose of systemic therapy within 3 months prior to trial…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Yale University, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT04974671 on ClinicalTrials.gov

4. Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

   This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab [Gazyva®] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned;…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   6 in total

   Run by

   Simcha IL-18, Inc.

   See if you can join NCT04787042 on ClinicalTrials.gov